Start here if you're new
what it is
PDS Biotechnology tries to train your immune system to attack cancer and infectious disease.
how it gets paid
Last year Pds Biotechnology made n/a in revenue. Versamune oncology was the main engine at $0M, or 40% of sales.
what just happened
PDSB posted a -$0.60 quarter while revenue still shows up as basically nothing.
At a glance
C+ balance sheet — struggling to keep the lights on
20/100 earnings predictability — expect surprises
-$1.03 fy2024 eps est
~$33M market cap
small cap
xvary composite: 28/100 — weak
What they do
PDS Biotechnology tries to train your immune system to attack cancer and infectious disease.
You are backing 24 employees and two platform families: Versamune and Infectimune. That is a small team trying to do a very hard biological job. If PDS01ADC or Versamune works, the payoff can be large. If the trials stall, you own a science project, not a business.
How they make money
n/a
annual revenue
Versamune oncology
$0M
PDS01ADC oncology
$0M
Infectimune infectious disease
$0M
Corporate and other
$0M
The products that matter
cancer immunotherapy platform
Versamune Platform
1 platform · $0 revenue
it underpins the entire company, which is exactly the issue: one platform supports the pipeline, but today that still means $0 revenue and a $33M equity value tied to unproven science.
entire thesis
Phase 3 lead program
VERSATILE-003
Phase 3 · protocol amended feb 2026
this is the lead value driver because management has made clear the story runs through Phase 3 progress. A February 2026 amendment is not failure, but it is proof that biotech timelines rarely move in straight lines.
binary catalyst
IL-12 fusion asset
PDS01ADC
jan 2026 update · $0 revenue
management highlighted this asset in a January 2026 update, but there is still $0 commercial revenue attached to it. For you, that means pipeline optionality, not product validation.
early optionality
Key numbers
-$1.03
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $12M (26% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for PDSB right now.
source: institutional data · return history unavailable
What just happened
missed estimates
PDSB posted a -$0.60 quarter while revenue still shows up as basically nothing.
The latest quarter showed a wider loss, and the business still has no meaningful sales base. That leaves the pipeline as the only real driver.
$0M
revenue
$0.60
eps
n/a
n/a
the number that mattered
The -$0.60 EPS matters because it shows the company is still spending without a sales engine behind it.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical failure or delay in VERSATILE-003.
med
Phase 3 disappointment breaks the equity story
There is no diversified revenue base behind this. The company is pre-revenue, and the platform case still runs through one lead Phase 3 program.
If VERSATILE-003 disappoints or slips materially, the market is left valuing $0 revenue, a $33M equity value, and a shrinking cash base. That usually resets the stock fast.
med
Cash burn can force dilution before the science resolves
The company posted a $9M Q3 2025 net loss, has $58.7M in total assets, and carries a C+ balance sheet. Dilution means issuing more shares to raise cash. In pre-revenue biotech, that is often the funding path.
With a $33M market cap, even a modest raise could change the ownership math before any product exists to support it.
med
The Nasdaq notice can become an operating problem
Trading below the $1 minimum bid triggered a March 3, 2026 deficiency notice. This is more than headline risk. Listing status affects who can own the stock and how easily the company can raise money.
Failure to regain compliance would pressure liquidity and make future financing harder. Bad setup for a company that already needs market access.
With $0 revenue, a $9M quarterly loss, and a $33M market cap, the combined risk picture is simple: one clinical setback or one financing round can rewrite the whole case.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
fy 2025 earnings report
Scheduled for March 26, 2026. For you, this is the cash-runway check as much as an earnings event.
trial trend
VERSATILE-003 execution
Track whether the February 2026 protocol amendment leads to cleaner progress or just pushes uncertainty further out.
listing risk
Nasdaq compliance path
The company needs to solve the sub-$1 bid issue. If it does not, liquidity risk moves from background noise to the main event.
valuation spread
the $3–$15 analyst range
That spread tells you analysts are not valuing a business. They are valuing a set of clinical outcomes. Same ticker. Very different futures.
Analyst rankings
earnings predictability
20 / 100
Low predictability means the next reported loss can land far from expectations. In human-speak, analysts do not have a steady business to model here.
risk rank
5
Risk rank is a stability score. A 5 means this sits near the speculative end of the market. You own it for upside, not sleep quality.
price stability
5 / 100
A 5/100 stability score means the chart can move like a headline feed. That matters because financing terms usually look worse when volatility is already high.
source: institutional data
Institutional activity
institutional ownership data for PDSB is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive